Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 34 Leukemia, Lymphocytic, Chronic, B-Cell 26 Myelodysplastic Syndromes 10 Lymphoma, Mantle-Cell 8 Neoplasms 7 Leukemia, Myelomonocytic, Chronic 7 Burkitt Lymphoma 7 Recurrence 5 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Multiple Myeloma 5 Lymphoma, Non-Hodgkin 5 Lymphoma, Follicular 5 Lymphoma, B-Cell, Marginal Zone 5 Lymphoma, B-Cell 5 Myeloproliferative Disorders 4 Lymphoma, Large B-Cell, Diffuse 4 Leukemia, Biphenotypic, Acute 4 Leukemia, B-Cell 4 Waldenstrom Macroglobulinemia 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Leukemia 3 Primary Myelofibrosis 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma 2 Hematologic Neoplasms 2 Hematologic Diseases 2 Thrombocytosis 1 Thrombocythemia, Essential 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1

Interventions

palbociclib 2 Letrozole 2 venetoclax 1 Fulvestrant 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Breast Neoplasm Female × venetoclax × Clear all

NCT03900884 2024-11-07

PALVEN

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡